Gubra A/S · OMXCOP:GUBRA
Gubra A/S — Q3 2026 Earnings Presentation
24 slides from Gubra A/S's earnings presentation, Nov 6, 2026
Slide 1: Investor presentation
Share ticker: GUBRA l Nasdaq Copenhagen Q3 l 6 NOVEMBER 2026 Investor presentation Present from Gubra: Markus Rohrwild, CEO Kristian Borbos, CFO Louise S. Dalbøge, CSO Thomas Langenickel, CMDO Zoë Johnson, Head of Ventures & BD Trine Hamann, Head of CRO Investor conference call 6 November 2026, 10:0
Slide 2: Forward-looking statements
Forward-looking statements ©2026 Gubra A/S ("Gubra"). All Gubra logos, trademarks and trade names are the property of Gubra A/S or its affiliates. Any third-party trademarks or tradenames referenced are the property of their respective owners and references do not imply third party endorsement or sp
Slide 3: Q3 2026: Significant R&D pipeline advancement and strong CRO performance
Q3 2026: Significant R&D pipeline advancement and strong CRO performance Gubra Gubra Gubra Biotech CRO Ventures Two partnered obesity 6% revenue growth both Actively evaluating new asset programs advanced to Phase 2 sequentially and year-on-year, and technology opportunities alongside initiation of
Slide 4: Gubra 2030: Scaling a differentiated drug discovery and development platform
Gubra 2030: Scaling a differentiated drug discovery and development platform GUBRA BY 2030 8-10 Three flagship 2-3 ventures Growing specialist clinical-stage therapeutic areas launched and preclinical CRO with assetsa and (Obesity and operated leadership in 1-2 DDCs/year CVRM, ARFD, I&I) high-value
Slide 5: Gubra Biotech
Gubra Biotech Our value driver 5
Slide 6: Differentiated R&D pipeline spanning proprietary and partnered programs
Differentiated R&D pipeline spanning proprietary and partnered programs GLP-1=glucagon-like peptide-1; NPY2R=neuropeptide Y receptor type 2; GLP-1R=glucagon-like peptide-1 receptor; GIPR=glucose-dependent insulinotropic polypeptide receptor; PBH=post-bariatric hypoglycemia; 6 PTH=parathyroid hormone
Slide 7: BI 3034701: Phase 2 trial has been initiated
BI 3034701: Phase 2 trial in people with overweight and obesity has been initiated for triple agonist (GLP-1/GIP/NPY2) Phase 1 studies for BI 3034701 demonstrated encouraging weight loss, alongside a favorable safety and tolerability profile, supporting advancement to Phase 2. PHASE 2 TRIAL1 344 par
Slide 8: ABBV-295 has consistently demonstrated encouraging clinical data throughout Phase 1 program
ABBV-295 has consistently demonstrated highly encouraging clinical data throughout a comprehensive Phase 1 program SAD study1 6-week MAD study2 12/13-week MAD study3 20-week Ph1b study4 % change in body weight % change in body weight % change in body weight Generating additional insights to from bas
Slide 9: Detailed data from the 12/13-week Phase 1 MAD trial of ABBV-295 presented at EASD 2026
Detailed data from the 12/13-week Phase 1 MAD trial of ABBV-295 presented at EASD 2026 % change in body weight1 Key highlights LS Mean (95% CI) Meaningful weight loss LS Mean (SE) Body Weight % CFB 2 % change at 1 Week 12 / 13 All Placebo + Up to ~10% body weight reduction over 12-13 (n = 15) 0 -0.2
Slide 10: AbbVie has initiated Phase 2 trial for ABBV-295
AbbVie has initiated Phase 2 trial for ABBV-295 in adults living with overweight and obesity Primary efficacy endpoint at week 32 supports timely evaluation of dose-response and dose selection for potential Phase 3 development, while treatment continues through week 52. PHASE 2 TRIAL1 Estimated 360
Slide 11: Three programs from Gubra collaborations beyond obesity advancing toward and through clinical development
BIOTECH Three programs from Gubra collaborations beyond obesity advancing toward and through clinical development Bleeding disorders, including Post-bariatric hypoglycemia Hypoparathyroidism heavy menstrual bleeding and other rare diseases + HMB-003a + AMX0318b + PTH analogc + Long-acting plasmin in
Slide 12: GUB-UCN2
GUB-UCN2 + Gubra’s next potential major value driver + Positions Gubra at the forefront of an emerging therapeutic class with multi-indication potential 12
Slide 13: GUB-UCN2's novel mechanism may unlock benefits across multiple organ systems
GUB-UCN2’s novel mechanism may unlock benefits across multiple organ systems UCN2 CRHR2 Downstream signaling Key features of GUB-UCN2 + 38-amino-acid neuropeptide + Highly potent and selective CRHR2 agonist Muscle mass + Excellent physical and chemical Adiposity and function Cardiac function Renal f
Slide 14: Pre-clinical data: GUB-UCN2 selectively reduces fat mass and restores tirzepatide-induced lean mass loss
Pre-clinical data: GUB-UCN2 selectively reduces fat mass and restores tirzepatide-induced lean mass loss GUB-UCN2 drives selective fat mass loss in DIO rats while preserving lean mass, alone and in combination with tirzepatide1 Body weight Fat mass Lean mass 110 20 15 Body weight (% of baseline) Fat
Slide 15: Comprehensive Phase 1/2a trial sets the stage for GUB-UCN2
Comprehensive Phase 1/2a trial sets the stage for GUB-UCN2 across multiple settings and patient populations Strategic GUB-UCN2 design Phase rational 1/2a trial1 Designed to: Key design elements + Assess safety and tolerability while capturing early efficacy signals in ambitious design ~188 participa
Slide 16: Gubra CRO
Gubra CRO Our value enabler 16
Slide 17: Gubra CRO strengthens and benefits from our integrated scientific platform
Gubra CRO strengthens and benefits from our integrated scientific platform Gubra + Reproducible + Reliable, high-quality data CRO + Deep scientific and preclinical disease and execution, customer Our value translational expertise models and advanced insight, and profitable enabler technology platfor
Slide 18: The preclinical CRO market is evolving in Gubra's direction
The preclinical CRO market is evolving in Gubra’s direction Scientific complexity Biotech funding has More preclinical R&D increases the value of rebounded strongly in 2026 is being outsourced specialist expertise and differentiated technology Biopharma equity raises1 Global discovery and preclinica
Slide 19: Gubra CRO delivered solid revenue growth and substantially improved profitability in Q3 2026
Gubra CRO delivered solid revenue growth and substantially improved profitability in Q3 2026 SOLID REVENUE GROWTH PROFITABILITY IMPROVEMENT COMMERCIAL MOMENTUM CRO external revenue CRO EBIT margin Solid order book DKK million entering Q4 2026 25% + Significant growth among +6% large pharma companies
Slide 20: Financial results and outlook
Financial results and outlook 20
Slide 21: Biotech business: 9M 2026 financial results
BIOTECH BUSINESS 9M 2026 financial results Revenue Biotech revenue, mDKK + Q3 2026 revenue of DKK 395m, driven by Phase 2 2,437 Q3 initiation milestones from AbbVie and Boehringer 50 Q2 Ingelheim Q1 425 2,380 + 9M 2026 revenue of DKK 425m, compared to DKK 2.4bn in 9M 2025, which included the upfront
Slide 22: CRO business: 9M 2026 financial results
CRO BUSINESS 9M 2026 financial results Revenue CRO revenue (external), mDKK + Q3 2026 external revenue reached DKK 52m, the 155 148 Q3 highest quarterly level of the year, with growth 49 52 Q2 both sequentially (+6.5%) and year-on-year Q1 55 49 (+5.6%) 51 48 + 9M 2026 external revenue of DKK 148m, d
Slide 23: Financial outlook and guidance
Financial outlook and guidance Key guidance items 2026 outlook Previous 2026 Mid-term guidance Results 2025 outlook Gubra Biotech Revenue No guidance No guidance DKK 2,444m Total costs1 DKK 315-335m DKK 330-360m DKK 251m Gubra CRO External revenue 2-6% growth 0-10% growth 10% annual growth DKK 193m
Slide 24: Gubra is entering an exciting period with multiple value inflection points ahead
Gubra is entering an exciting period with multiple value inflection points ahead Non-exhaustive H2 2026 H1 2027 GUB-UCN2 GUB-UCN2 Ph1/2a initiation (SAD study) Topline data from SAD study BI 3034701 GUB-UCN2 Ph2 initiation (obesity) Initiation of MAD study ABBV-295 ABBV-295 Ph2 initiation (obesity)